Molecule
Ferric oxyhydroxide is a phosphate binder indicated for the control of serum phosphorus levels in adults and pediatric patients 6 years of age and older with chronic kidney disease (CKD) on dialysis. MedsAcross supplies Ferric oxyhydroxide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Velphoro is indicated for the control of serum phosphorus levels in adults and pediatric patients 6 years of age and older with chronic kidney disease (CKD) on dialysis. Velphoro is a phosphate binder indicated for the control of serum phosphorus levels in adult and pediatric patients 6 years of age and older with chronic kidney disease on dialysis.
Source: US FDA prescribing information
In the aqueous environment of the GI tract, phosphate binding takes place by ligand exchange between hydroxyl groups and/or water in sucroferric oxyhydroxide and the phosphate in the diet. The bound phosphate is eliminated with feces. Both serum phosphorus levels and calcium-phosphorus product levels are reduced as a consequence of the reduced dietary phosphate absorption.
Source: US FDA prescribing information
Chew or crush Velphoro tablets, do not swallow whole. Administer orally with meals. Dosage Information. Recommended Starting Dosage Dosage Adjustments Adults and pediatric patients 12 years of age and older 500 mg three times daily 500 mg per day Pediatric patients 9 to less than 12 years of age 500 mg two times daily 500 mg per day Pediatric patients 6 to less than 9 years of age 250 mg three times daily 250 mg per day Adjust dosage as needed until an acceptable serum phosphorus level is reached, with regular monitoring afterwards. Titrate as often as weekly.
Source: US FDA prescribing information
None. None
Source: US FDA prescribing information
Patients with peritonitis during peritoneal dialysis, significant gastric or hepatic disorders, history of recent major gastrointestinal surgery, or with a history of hemochromatosis or other diseases with iron accumulation have not been included in clinical studies with Velphoro. Monitor effect and iron homeostasis in such patients.
Source: US FDA prescribing information
The most common adverse drug reactions to Velphoro chewable tablets in clinical trials were discolored feces (12%) and diarrhea (6%).
Source: US FDA prescribing information
Table 2 Administration of Velphoro with other oral drugs Drug Dosing recommendations Oral drugs that may be administered concomitantly with Velphoro Calcitriol, Ciprofloxacin, Digoxin, Enalapril, Furosemide, HMG-CoA reductase inhibitors, Hydrochlorothiazide, Losartan, Metoprolol, Nifedipine, Omeprazole, Quinidine, Warfarin No dose separation required Oral drugs that are to be separated from Velphoro Doxycycline, Acetylsalicylic acid, Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro. Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Velphoro and most concomitant oral drugs. For oral medications where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, consider separating the administration of the two drugs.
Source: US FDA prescribing information
Store at 25°C (77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Ferric oxyhydroxide, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Velphoro 250 mg chewable tabletOral | Fresenius Medical Care Renal Therapies Group | US FDA | Available on request |
| Velphoro 500 mg chewable tabletOral | Fresenius Medical Care Renal Therapies Group | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 27 November 2013 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 2 presentations of Ferric oxyhydroxide and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Ferric oxyhydroxide, including Velphoro.
Yes. The US FDA first approved Ferric oxyhydroxide on 27 November 2013, according to Drugs@FDA.
No listed presentation of Ferric oxyhydroxide is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.